Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000333360 | SCV000342106 | uncertain significance | not provided | 2017-07-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000333360 | SCV001040344 | likely benign | not provided | 2022-04-18 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000333360 | SCV001785441 | uncertain significance | not provided | 2021-09-15 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004678664 | SCV005176242 | uncertain significance | Inborn genetic diseases | 2024-04-12 | criteria provided, single submitter | clinical testing | The c.908C>T (p.P303L) alteration is located in exon 5 (coding exon 5) of the TJP2 gene. This alteration results from a C to T substitution at nucleotide position 908, causing the proline (P) at amino acid position 303 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003957494 | SCV004771313 | likely benign | TJP2-related disorder | 2023-04-17 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |